vs
Side-by-side financial comparison of NexPoint Real Estate Finance, Inc. (NREF) and STRATA Skin Sciences, Inc. (SSKN). Click either name above to swap in a different company.
NexPoint Real Estate Finance, Inc. is the larger business by last-quarter revenue ($11.1M vs $9.3M, roughly 1.2× STRATA Skin Sciences, Inc.). NexPoint Real Estate Finance, Inc. runs the higher net margin — 216.6% vs 0.6%, a 216.0% gap on every dollar of revenue. On growth, STRATA Skin Sciences, Inc. posted the faster year-over-year revenue change (-3.0% vs -48.8%).
NexPoint Real Estate Finance, Inc. is a US-based commercial real estate finance firm that offers structured financing solutions for multifamily, office, industrial, and hospitality properties. It focuses on originating, managing and servicing a diversified portfolio of mortgage loans and real estate-related investments to deliver stable risk-adjusted returns to stakeholders.
Strata Skin Sciences is an American medical device company focused on the design, development and commercialization of non-invasive tools to provide additional information to dermatologists during melanoma skin examinations.
NREF vs SSKN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $11.1M | $9.3M |
| Net Profit | $24.0M | $58.0K |
| Gross Margin | — | 61.8% |
| Operating Margin | — | 5.3% |
| Net Margin | 216.6% | 0.6% |
| Revenue YoY | -48.8% | -3.0% |
| Net Profit YoY | 58.7% | 101.3% |
| EPS (diluted) | $0.47 | $0.14 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $11.1M | $9.3M | ||
| Q3 25 | $12.5M | $6.9M | ||
| Q2 25 | $12.1M | $7.7M | ||
| Q1 25 | $11.5M | $6.8M | ||
| Q4 24 | $21.7M | $9.6M | ||
| Q3 24 | $12.5M | $8.8M | ||
| Q2 24 | $6.7M | $8.4M | ||
| Q1 24 | $-12.8M | $6.8M |
| Q4 25 | $24.0M | $58.0K | ||
| Q3 25 | $50.9M | $-1.6M | ||
| Q2 25 | $22.3M | $-2.6M | ||
| Q1 25 | $26.0M | $-2.1M | ||
| Q4 24 | $15.2M | $-4.6M | ||
| Q3 24 | $23.3M | $-2.1M | ||
| Q2 24 | $12.1M | $-91.0K | ||
| Q1 24 | $-14.6M | $-3.4M |
| Q4 25 | — | 61.8% | ||
| Q3 25 | — | 60.4% | ||
| Q2 25 | — | 56.2% | ||
| Q1 25 | — | 53.5% | ||
| Q4 24 | — | 61.4% | ||
| Q3 24 | — | 60.1% | ||
| Q2 24 | — | 59.0% | ||
| Q1 24 | — | 45.6% |
| Q4 25 | — | 5.3% | ||
| Q3 25 | — | -16.9% | ||
| Q2 25 | — | -30.1% | ||
| Q1 25 | — | -25.0% | ||
| Q4 24 | — | -44.7% | ||
| Q3 24 | — | -18.2% | ||
| Q2 24 | — | -5.7% | ||
| Q1 24 | — | -42.7% |
| Q4 25 | 216.6% | 0.6% | ||
| Q3 25 | 407.0% | -23.4% | ||
| Q2 25 | 184.5% | -33.6% | ||
| Q1 25 | 225.6% | -31.2% | ||
| Q4 24 | 69.9% | -47.6% | ||
| Q3 24 | 186.4% | -23.6% | ||
| Q2 24 | 179.7% | -1.1% | ||
| Q1 24 | 114.3% | -49.8% |
| Q4 25 | $0.47 | $0.14 | ||
| Q3 25 | $1.14 | $-0.36 | ||
| Q2 25 | $0.54 | $-0.62 | ||
| Q1 25 | $0.70 | $-0.51 | ||
| Q4 24 | $0.71 | $-2.01 | ||
| Q3 24 | $0.74 | $-0.51 | ||
| Q2 24 | $0.40 | $-0.03 | ||
| Q1 24 | $-0.83 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $31.1M | $7.9M |
| Total DebtLower is stronger | $771.2M | $15.3M |
| Stockholders' EquityBook value | $388.0M | $2.9M |
| Total Assets | $5.3B | $30.5M |
| Debt / EquityLower = less leverage | 1.99× | 5.28× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $31.1M | $7.9M | ||
| Q3 25 | $17.9M | $7.1M | ||
| Q2 25 | $9.1M | $6.0M | ||
| Q1 25 | $19.2M | $6.5M | ||
| Q4 24 | $3.9M | $7.3M | ||
| Q3 24 | $34.7M | $7.1M | ||
| Q2 24 | $4.3M | $5.5M | ||
| Q1 24 | $13.5M | $5.2M |
| Q4 25 | $771.2M | $15.3M | ||
| Q3 25 | $720.9M | $15.3M | ||
| Q2 25 | $815.6M | $15.0M | ||
| Q1 25 | $831.5M | $15.0M | ||
| Q4 24 | $799.3M | $15.0M | ||
| Q3 24 | $815.5M | $15.0M | ||
| Q2 24 | $861.0M | $15.0M | ||
| Q1 24 | $843.3M | $15.0M |
| Q4 25 | $388.0M | $2.9M | ||
| Q3 25 | $375.4M | $1.3M | ||
| Q2 25 | $348.2M | $532.0K | ||
| Q1 25 | $343.7M | $3.0M | ||
| Q4 24 | $336.5M | $5.0M | ||
| Q3 24 | $335.8M | $9.4M | ||
| Q2 24 | $327.5M | $9.5M | ||
| Q1 24 | $327.1M | $9.4M |
| Q4 25 | $5.3B | $30.5M | ||
| Q3 25 | $5.3B | $30.7M | ||
| Q2 25 | $5.4B | $29.5M | ||
| Q1 25 | $5.4B | $33.0M | ||
| Q4 24 | $5.4B | $34.9M | ||
| Q3 24 | $5.7B | $39.4M | ||
| Q2 24 | $6.6B | $38.8M | ||
| Q1 24 | $7.1B | $39.2M |
| Q4 25 | 1.99× | 5.28× | ||
| Q3 25 | 1.92× | 11.65× | ||
| Q2 25 | 2.34× | 28.20× | ||
| Q1 25 | 2.42× | 5.04× | ||
| Q4 24 | 2.38× | 3.02× | ||
| Q3 24 | 2.43× | 1.60× | ||
| Q2 24 | 2.63× | 1.58× | ||
| Q1 24 | 2.58× | 1.59× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-4.5M | $-239.0K |
| Free Cash FlowOCF − Capex | — | $-551.0K |
| FCF MarginFCF / Revenue | — | -5.9% |
| Capex IntensityCapex / Revenue | — | 3.4% |
| Cash ConversionOCF / Net Profit | -0.19× | -4.12× |
| TTM Free Cash FlowTrailing 4 quarters | — | $-4.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-4.5M | $-239.0K | ||
| Q3 25 | $8.1M | $-64.0K | ||
| Q2 25 | $3.3M | $-1.9M | ||
| Q1 25 | $16.0M | $-550.0K | ||
| Q4 24 | $4.4M | $703.0K | ||
| Q3 24 | $14.7M | $-302.0K | ||
| Q2 24 | $-7.5M | $591.0K | ||
| Q1 24 | $17.7M | $-804.0K |
| Q4 25 | — | $-551.0K | ||
| Q3 25 | — | $-1.1M | ||
| Q2 25 | — | $-2.0M | ||
| Q1 25 | — | $-749.0K | ||
| Q4 24 | — | $199.0K | ||
| Q3 24 | — | $-364.0K | ||
| Q2 24 | — | $246.0K | ||
| Q1 24 | — | $-1.5M |
| Q4 25 | — | -5.9% | ||
| Q3 25 | — | -15.6% | ||
| Q2 25 | — | -26.1% | ||
| Q1 25 | — | -11.0% | ||
| Q4 24 | — | 2.1% | ||
| Q3 24 | — | -4.1% | ||
| Q2 24 | — | 2.9% | ||
| Q1 24 | — | -22.6% |
| Q4 25 | — | 3.4% | ||
| Q3 25 | — | 14.7% | ||
| Q2 25 | — | 0.8% | ||
| Q1 25 | — | 2.9% | ||
| Q4 24 | — | 5.3% | ||
| Q3 24 | — | 0.7% | ||
| Q2 24 | — | 4.1% | ||
| Q1 24 | — | 10.7% |
| Q4 25 | -0.19× | -4.12× | ||
| Q3 25 | 0.16× | — | ||
| Q2 25 | 0.15× | — | ||
| Q1 25 | 0.62× | — | ||
| Q4 24 | 0.29× | — | ||
| Q3 24 | 0.63× | — | ||
| Q2 24 | -0.62× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NREF
Segment breakdown not available.
SSKN
| Dermatology Recurring Procedures | $6.1M | 65% |
| Dermatology Procedures Equipment | $3.2M | 35% |
